TY - JOUR
T1 - Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
AU - Dagan, Ron
AU - Melamed, Rimma
AU - Muallem, Marie
AU - Piglansky, Lolita
AU - Greenberg, David
AU - Abramson, Oren
AU - Mendelman, Paul M.
AU - Bohidar, Norman
AU - Yagupsky, Pablo
N1 - Funding Information:
Received 20 February 1995; revised 17 July 1996. Presented in part: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1995 (abstract 02). The study was approved by local and national ethics committees. An informed consent statement was signed by the infants' parents. Grant support: Merck Research Laboratories, West Point, Pennsylvania. Reprints or correspondence: Dr. Ron Dagan, Pediatric Infectious Disease Unit, Soroka University Medical Center, P.O. Box 151, Beer-Sheva 84101, Israel.
PY - 1996/1/1
Y1 - 1996/1/1
N2 - Children 12-18 months old were randomized to receive one dose of a conjugate heptavalent pneumococcal vaccine, two doses of the same vaccine, or one dose of a 23-valent native polysaccharide vaccine. Before immunization, pneumococci included in the conjugate vaccine were isolated from 24% of the children, and an antibiotic-resistant pneumococcus was isolated from 22% of the children. The vaccines had no effect on carriage of non-vaccine-type pneumococci. In contrast, there was a significant reduction in carriage of vaccine-type pneumococci 3 months after one dose and I month after a second dose of conjugate vaccine (from 25% to 9% and 7%, respectively; P < .001). No effect was seen after vaccination with the nonconjugate vaccine. One year after immunization, carriage of antibiotic-resistant vaccine-type pneumococci in children receiving conjugate vaccine was lower than that in children receiving the nonconjugate vaccine (4% vs. 14%, P = .042). Conjugate pneumococcal vaccines may reduce spread of pneumococci in the community.
AB - Children 12-18 months old were randomized to receive one dose of a conjugate heptavalent pneumococcal vaccine, two doses of the same vaccine, or one dose of a 23-valent native polysaccharide vaccine. Before immunization, pneumococci included in the conjugate vaccine were isolated from 24% of the children, and an antibiotic-resistant pneumococcus was isolated from 22% of the children. The vaccines had no effect on carriage of non-vaccine-type pneumococci. In contrast, there was a significant reduction in carriage of vaccine-type pneumococci 3 months after one dose and I month after a second dose of conjugate vaccine (from 25% to 9% and 7%, respectively; P < .001). No effect was seen after vaccination with the nonconjugate vaccine. One year after immunization, carriage of antibiotic-resistant vaccine-type pneumococci in children receiving conjugate vaccine was lower than that in children receiving the nonconjugate vaccine (4% vs. 14%, P = .042). Conjugate pneumococcal vaccines may reduce spread of pneumococci in the community.
UR - http://www.scopus.com/inward/record.url?scp=0029828246&partnerID=8YFLogxK
U2 - 10.1093/infdis/174.6.1271
DO - 10.1093/infdis/174.6.1271
M3 - Article
AN - SCOPUS:0029828246
VL - 174
SP - 1271
EP - 1278
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 6
ER -
